Hepatobiliary phenotypes of adults with alpha-1 antitrypsin deficiency
- 25 February 2021
- Vol. 71 (2), 415-423
- https://doi.org/10.1136/gutjnl-2020-323729
Abstract
Objective Alpha-1 antitrypsin deficiency (AATD) is a common, potentially lethal inborn disorder caused by mutations in alpha-1 antitrypsin (AAT). Homozygosity for the ‘Pi*Z’ variant of AAT (Pi*ZZ genotype) causes lung and liver disease, whereas heterozygous ‘Pi*Z’ carriage (Pi*MZ genotype) predisposes to gallstones and liver fibrosis. The clinical significance of the more common ‘Pi*S’ variant remains largely undefined and no robust data exist on the prevalence of liver tumours in AATD. Design Baseline phenotypes of AATD individuals and non-carriers were analysed in 482 380 participants in the UK Biobank. 1104 participants of a multinational cohort (586 Pi*ZZ, 239 Pi*SZ, 279 non-carriers) underwent a comprehensive clinical assessment. Associations were adjusted for age, sex, body mass index, diabetes and alcohol consumption. Results Among UK Biobank participants, Pi*ZZ individuals displayed the highest liver enzyme values, the highest occurrence of liver fibrosis/cirrhosis (adjusted OR (aOR)=21.7 (8.8–53.7)) and primary liver cancer (aOR=44.5 (10.8–183.6)). Subjects with Pi*MZ genotype had slightly elevated liver enzymes and moderately increased odds for liver fibrosis/cirrhosis (aOR=1.7 (1.2–2.2)) and cholelithiasis (aOR=1.3 (1.2–1.4)). Individuals with homozygous Pi*S mutation (Pi*SS genotype) harboured minimally elevated alanine aminotransferase values, but no other hepatobiliary abnormalities. Pi*SZ participants displayed higher liver enzymes, more frequent liver fibrosis/cirrhosis (aOR=3.1 (1.1–8.2)) and primary liver cancer (aOR=6.6 (1.6–26.9)). The higher fibrosis burden was confirmed in a multinational cohort. Male sex, age ≥50 years, obesity and the presence of diabetes were associated with significant liver fibrosis. Conclusion Our study defines the hepatobiliary phenotype of individuals with the most relevant AATD genotypes including their predisposition to liver tumours, thereby allowing evidence-based advice and individualised hepatological surveillance.Keywords
Funding Information
- CSL Behring (N/A)
- Deutsche Forschungsgemeinschaft (consortium SFB/TRR57 “Liver fibrosis”, grant STR1095/6-1)
- Arrowhead Pharmaceuticals (N/A)
- EASL registry grant on alpha-1 antitrypsin-related liver disease (N/A)
This publication has 33 references indexed in Scilit:
- PiSZ alpha-1 antitrypsin deficiency (AATD): pulmonary phenotype and prognosis relative to PiZZ AATD and PiMM COPDThorax, 2015
- Baseline Analysis of a Young α‐1‐Antitrypsin Deficiency Liver Disease Cohort Reveals Frequent Portal HypertensionJournal of Pediatric Gastroenterology and Nutrition, 2015
- Spanish Registry of Patients With Alpha-1 Antitrypsin Deficiency; Comparison of the Characteristics of PISZ and PIZZ IndividualsCOPD: Journal of Chronic Obstructive Pulmonary Disease, 2015
- Addressing liver disease in the UK: a blueprint for attaining excellence in health care and reducing premature mortality from lifestyle issues of excess consumption of alcohol, obesity, and viral hepatitisThe Lancet, 2014
- Prevalence of α1-antitrypsin deficiency alleles PI*S and PI*Z worldwide and effective screening for each of the five phenotypic classes PI*MS, PI*MZ, PI*SS, PI*SZ, and PI*ZZ: a comprehensive reviewTherapeutic Advances in Respiratory Disease, 2012
- Liver Test Results Do Not Identify Liver Disease in Adults With α1-Antitrypsin DeficiencyClinical Gastroenterology and Hepatology, 2012
- Evolution of indications and results of liver transplantation in Europe. A report from the European Liver Transplant Registry (ELTR)Journal of Hepatology, 2012
- Is PiSS Alpha-1 Antitrypsin Deficiency Associated with Disease?Pulmonary Medicine, 2010
- Alpha1-Antitrypsin DeficiencyThe New England Journal of Medicine, 2009
- Analyses of hepatocellular proliferation in a mouse model of α-1-antitrypsin deficiencyJournal of Hepatology, 2004